---
title: "Skyrizi (risankizumab-rzaa) in plaque psoriasis: Storage and supply questions"
description: "Storage and supply questions on Skyrizi (risankizumab-rzaa) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: How supplied. Questions: What forms and strengths does Skyrizi come in for psoriasis? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/storage-and-supply"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa) in plaque psoriasis: Storage and supply questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)

Storage and supply questions that apply to every indication of Skyrizi are on [Skyrizi (risankizumab-rzaa), all indications: Storage and supply](https://www.evicenter.com/medical-information/skyrizi/storage-and-supply).

## How supplied

<a id="skyrizi-dosage-forms"></a>

### What forms and strengths does Skyrizi come in for psoriasis?

> “Subcutaneous Injection: colorless to yellow, and clear to slightly opalescent solution. 
> SKYRIZI Pen 
> • Injection: 150 mg/mL in a single-dose prefilled pen. 
> SKYRIZI Prefilled Syringe 
> • Injection: 55 mg/0.37 mL in a single-dose prefilled syringe. 
> • Injection: 150 mg/mL in a single-dose prefilled syringe. 
> • Injection: 180 mg/1.2 mL (150 mg/mL) in a single-dose prefilled syringe.”

Source: [SKYRIZI: Prescribing information, page 7, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=7)

> “SKYRIZI is also available in a single-dose 150 mg/mL prefilled syringe.<sup>1</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Injection Pen for Ps and PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/dosing/pso-psa-injection-device#:~:text=SKYRIZI%20is%20also%20available%20in%20a%20single%2Ddose%20150%20mg%2FmL%20prefilled)

Note: The 55 mg/0.37 mL prefilled syringe is the pediatric dose for patients weighing less than 40 kg. The 180 mg/1.2 mL prefilled syringe is used for Crohn’s disease and ulcerative colitis, as are the prefilled cartridges with on-body injector and the intravenous vial that the label also lists.

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/access-and-coverage)
